CEFTRIAXONE SODIUM Drug Patent Profile

Which patents cover Ceftriaxone Sodium, and what generic alternatives are available?

Ceftriaxone Sodium is a drug marketed by Anda Repository and Hikma and is included in two NDAs.

The generic ingredient in CEFTRIAXONE SODIUM is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ceftriaxone Sodium

A generic version of CEFTRIAXONE SODIUM was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20^th, 2017.

Summary for CEFTRIAXONE SODIUM

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for CEFTRIAXONE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Anda Repository	CEFTRIAXONE SODIUM	ceftriaxone sodium	INJECTABLE;INJECTION	091117-001	Jan 20, 2017	AP	RX	No	No
Hikma	CEFTRIAXONE SODIUM	ceftriaxone sodium	INJECTABLE;INJECTION	090701-001	Oct 4, 2017	AP	RX	No	No

Cephalosporin Antibiotic CEFTRIAXONE SODIUM Investment Scenario and Patent/Exclusivity Fundamentals Analysis

Last updated: July 30, 2026

CeFTRIAXONE SODIUM is an off-patent, widely genericized injectable cephalosporin with mature FDA manufacturing supply and limited near-term IP optionality. Investment cases hinge on (1) competitive differentiation in formulation and use-driven product lifecycle management, (2) procurement and contracting dynamics, and (3) liability and regulatory execution in sterile manufacturing. Patent and regulatory headwinds are structural, with most brand-origin exclusivities long expired and generic entry risks already priced into the market.

What patents protect ceftriaxone sodium, and how strong is the patent estate?

Answer: For ceftriaxone sodium itself, the core active-ingredient patent estate is largely expired. Current IP, where it exists, typically concentrates in specific injectable presentations, sterile manufacturing processes, specific combination products (if any), and method-of-use claims that are often narrow and less enforceable against conventional generics.

Which patent categories still matter for ceftriaxone sodium investors?

For a commodity beta-lactam like ceftriaxone sodium, surviving value is usually tied to one of these:

• Formulation patents (vehicle, stability, lyophilization approach, solubilization system, pH/buffering strategy) that protect specific branded strengths, packaging configurations, or reconstitution behavior.
• Sterile manufacturing process patents (aseptic processing parameters, filtration/sterilization steps, bulk-to-finished conversion controls).
• Method-of-use patents (rare in mature antibiotics unless tied to a defined regimen or patient subset and supported by strong clinical data).
• Second-generation improvements (different dosing devices, ready-to-use formats, or combination products).

Practical consequence for exclusivity and licensing

• Even if formulation or process patents exist in select jurisdictions, they usually do not block entry at the API level and often cover only a specific product configuration.
• For licensing strategy, enforceability against an entrant manufacturing a conventional generic is often constrained by claim scope and design-around feasibility.

How many patents cover ceftriaxone sodium?

Investment implication: If an investor is modeling incremental monopoly cash flows, the baseline assumption for ceftriaxone sodium should be high likelihood of generic parity, with IP only protecting incremental product variants. Without a specific branded product identity (e.g., a specific NDA/BLA or a particular product strength and presentation), a reliable “count” of enforceable patents is not actionable at the asset level.

When does ceftriaxone sodium lose exclusivity, and what exclusivity still exists in practice?

Answer: Ceftriaxone sodium’s market exclusivity from the original innovator is well beyond typical timelines. In practice, what investors should track is presentation-level exclusivity (if any) and regulatory exclusivity attached to specific NDAs rather than API-level exclusivity.

Regulatory exclusivity vs. patent exclusivity: what actually blocks generics?

• Patent exclusivity ends when patents expire or are invalidated or designed around.
• Orange Book “listed patents” are the relevant screen for FDA-based launch barriers for an NDA holder.
• Statutory exclusivities (pediatric, new clinical investigation, etc.) may attach to a specific NDA, but these are uncommon for old, widely used antibiotic injectables unless tied to a later NDA line extension.

Timing model investors use

For a mature injectable antibiotic, the practical exclusivity timeline is usually already passed. The investment “timing edge” shifts to:

• Pending product line approvals (new presentations, new suppliers, new packaging formats).
• Antimicrobial stewardship and payer contracting cycles that govern demand, not exclusivity.

What is the Orange Book status of ceftriaxone sodium products?

Answer: Orange Book coverage exists at the specific NDA level, not the API name level. For an off-patent drug, the Orange Book typically shows at most a small set of listed patents with expiration already reached, and generics frequently enter as standard ANDA approvals once bioequivalence and chemistry controls are satisfied.

What to verify in Orange Book for investment diligence

Investors should confirm for each target product SKU:

• Active ingredients/strength
• NDA holder and labeler
• Patent list with expiration dates
• Any pediatric exclusivity or regulatory exclusivity codes
• Whether listed patents are “orange book live” or already expired

How many ANDAs exist for ceftriaxone sodium, and what generic entry risks exist?

Answer: Ceftriaxone sodium has extensive generic competition with high ANDA density. Generic entry risk is structurally high, with barriers mainly tied to sterile manufacturing capability, regulatory compliance, and supply continuity rather than IP.

What launch barriers are real for an investor?

• Sterile facility capability: aseptic process validation, media fills, ongoing sterility assurance, and batch release control.
• Supply chain resilience: API sourcing, bulk stability, and temperature-controlled logistics.
• Quality system maturity: deviation rates, CAPA cycle times, analyst qualification, and equipment qualification.

Competitive landscape implication

If a company cannot differentiate on reliability, cost, or contract terms, price competition compresses margins quickly after approvals.

Which companies are selling ceftriaxone sodium in the US, and how does the supply landscape affect pricing?

Answer: The US injectable cephalosporin market is dominated by large generic manufacturers and specialty sterile producers, with pricing driven by contracting and procurement cycles. The most important differentiator is supply reliability rather than patent position.

Supply-driven margin model

• Shortages can temporarily improve pricing power.
• Once supply normalizes, margins fall toward generic commodity levels.

Investment readthrough

An investor should underwrite:

• procurement contract exposure
• facility redundancy and backup API arrangements
• regulatory inspection history
• ability to ramp supply after FDA approvals and internal transfers

What formulations of ceftriaxone sodium are protected, and do formulation patents block generics?

Answer: In mature generics markets, formulation patents rarely block conventional generics unless they are tightly tied to a specific protected presentation and are actively listed for a relevant NDA.

Typical ceftriaxone sodium presentation drivers

• Powder for injection vs. premixed diluent systems
• Strengths and vial sizes that map to hospital formularies
• Reconstitution stability and compatibility (IV line compatibility is a key user outcome)

What this means for litigation risk

• Most generic entrants can design around non-critical formulation features.
• Litigation, if any, typically targets narrow aspects of a presentation rather than blocking all ceftriaxone sodium supply.

What patent litigation affects ceftriaxone sodium, and what settlements matter for investors?

Answer: With an off-patent, widely genericized antibiotic, patent litigation tends to be sporadic and usually presentation-specific. A credible litigation-driven investment thesis requires identifying an active case tied to a particular NDA and a still-live patent.

Litigation diligence checklist

• active Paragraph IV filings tied to a specific Orange Book listed patent
• district court case status and claim construction outcomes
• settlement terms such as “carve-outs” for specific strengths or presentations

What FDA regulatory pathway is used for ceftriaxone sodium generics (ANDA vs. 505(b)(2)?

Answer: Generics of ceftriaxone sodium are typically pursued via ANDAs. Changes that require clinical or formulation enhancements can sometimes support 505(b)(2) or supplemental approvals, but for a commodity injectable, ANDA remains dominant.

Investor implications by pathway

• ANDA: faster route when bioequivalence and formulation equivalence are straightforward.
• 505(b)(2): may support limited lifecycle extension but often does not create durable premium pricing.

How does ceftriaxone sodium compare with competing cephalosporins for investment fundamentals?

Answer: Competitive pressure is intense across beta-lactam injectables, but differentiation can exist in:

• spectrum alignment to guideline-based use
• hospital formulary preferences
• supply reliability and contract economics
• evidence-based stewardship programs

Competitive set investors should benchmark

• other third-generation cephalosporins used for similar indications (e.g., cefotaxime, ceftazidime when used clinically in overlapping settings)
• broader-spectrum alternatives if payer formularies shift

What commercial metrics matter most for investing in ceftriaxone sodium?

Answer: For a mature injectable antibiotic, investment fundamentals align to supply chain reliability and contracting, not IP. Key metrics:

• net sales growth by contract cycle
• gross margin stability through commodity price cycles
• procurement allocation and customer concentration risk
• inspection outcomes and compliance costs
• facility utilization and batch yield

Revenue exposure model

• If a manufacturer depends on a single sterile facility, downtime risk is material.
• If diversified across sites with validated transfers, the company can capture shortage-driven pricing windows.

What generic launch scenarios exist for ceftriaxone sodium, and what impact do they have on pricing?

Answer: The “scenario” for ceftriaxone sodium is typically:

• approval and entry at near-parity pricing
• aggressive contracting
• margin compression unless there is a supply disruption

Investment underwriting

• model a base case with rapid price normalization after approvals
• model upside tied to supply constraints or regulatory disruptions at competitors
• model downside tied to inspection issues, batch failures, or API sourcing interruptions

What manufacturing/IP barriers protect ceftriaxone sodium products from new entrants?

Answer: The strongest barriers are practical, not patent-based:

• sterile manufacturing competence
• process validation credibility
• consistent quality release
• capacity to supply large-volume hospital contracting

IP vs. manufacturing barrier comparison

• IP: usually narrow presentation-level coverage, design-around feasible
• Manufacturing: harder to replicate quickly and directly affects patient supply continuity

Key Takeaways

• Ceftriaxone sodium is an off-patent, generic-dense antibiotic where durable exclusivity is not the primary value driver.
• Investment upside typically comes from operational execution: reliable sterile manufacturing, contract win rates, and supply chain resilience.
• IP still matters only at the SKU level (specific presentations, formulation/process improvements tied to live patents on specific NDAs).
• Generic entry risk is high and competition compresses margins quickly after approvals.
• The strongest diligence focus is quality system, inspection risk, capacity, API sourcing redundancy, and contracting dynamics, not long-duration patent monopolies.

FAQs

1. How do sterile manufacturing quality events affect ceftriaxone sodium supply and margins?
2. What contract and procurement factors determine ceftriaxone sodium pricing more than API-level patents?
3. Which Orange Book fields most directly predict whether an NDA launch is blocked for ceftriaxone sodium?
4. How do shortage-driven pricing windows typically normalize after new ceftriaxone sodium approvals?
5. What formulation changes are most likely to create defensible, presentation-specific IP in ceftriaxone sodium injectables?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. ANDA Guidance documents and current regulatory framework for generic drug approval pathways. U.S. Food and Drug Administration.
3. FDA. Statutory exclusivity and regulatory exclusivity explanations (including 7-year, 5-year, and related provisions). U.S. Food and Drug Administration.